Os carcinomas da tireóide são as neoplasias malignas mais freqüentes do sistema endócrino. Classificam-se histologicamente em carcinomas papilar e folicular, derivados das células foliculares; carcinoma medular, derivado das células C ou parafoliculares, e carcinoma anaplásico. Os carcinomas diferenciados, papilar e folicular, representam mais do que 85% de todos os tipos histológicos. O carcinoma medular, compreende 5 a 10% e o anaplásico ou indiferenciado, 2% de todos os cânceres da tireóide. Os carcinomas diferenciados da tireóide geralmente conservam as características bioquímicas da célula folicular tireoidiana. No entanto, vários estudos têm descrito anormalidades na expressão das principais proteínas envolvidas na biossíntese dos hormônios tireoidianos, tais como o receptor do TSH, o cotransportador de Na+/I- (NIS), a tireoglobulina (Tg) e a tireoperoxidase (TPO). As iodotironinas desiodases tipo 1 (D1) e tipo 2 (D2) são enzimas responsáveis pela ativação do T4 e produção do hormônio biologicamente ativo T3 na tireóide e nos tecidos periféricos. Poucos estudos analisaram a expressão das 5’-desiodases nos carcinomas diferenciados da tireóide. Estudos prévios demonstraram que a expressão da isoenzima D2 está reduzida no carcinoma papilar e aumentada no carcinoma folicular metastático. No entanto, uma expressão variável da D1 foi descrita em amostras de carcinomas papilares, sendo que não havia uma avaliação sistemática da expressão dessa isoenzima nos carcinomas foliculares. O objetivo inicial do nosso estudo foi avaliar a expressão da D1 e da D2 nos tumores benignos e malignos da tireóide. De forma interessante, demonstramos que nos vários subtipos histológicos de carcinoma papilar, inclusive em microcarcinomas, os níveis de RNA mensageiro (RNAm) e de atividade da D1 estavam significativamente diminuídos em relação ao tecido tireoidiano normal correspondente (0,25 ± 0,24 vs. 1,09 ± 0,54 unidades arbitrárias (UA), P<0,001 e 0,08 ± 0,07 vs. 0,24 ± 0,15 pmol T4/min/mg proteína, P=0,045, respectivamente) . Por outro lado, observamos um aumento da expressão dessa enzima nos adenomas (1,9 ± 1,5 vs. 0,83 ± 0,58 UA, P= 0,028 e 2,67 ± 1,42 vs. 0,22 ± 0,06 pmol T4/min/mg proteína, P=0,044, respectivamente) e nos carcinomas foliculares (1,2 ± 0,46 vs. 0,67 ± 0,18 UA, P=0,038 e 1,20 ± 0,58 vs. 0,20 ± 0,10 pmol T4/min/mg proteína, P<0,001, respectivamente). Da mesma forma, confirmamos dados prévios sobre o aumento da atividade da D2 no carcinoma folicular metastático. A análise desses resultados permitiu concluir, originalmente, que a alteração na expressão da D1 parece ser um evento precoce e específico da desdiferenciação celular do carcinoma papilar (Souza Meyer EL et al, Clinical Endocrinology 2005;62:672-78). O interesse pelo padrão de expressão das 5’-desiodases em outros tumores humanos e pelos mecanismos ou implicações do aumento ou da diminuição das desiodases na patogênese neoplásica, determinou um estudo da literatura que foi publicado em artigo de revisão (Meyer ELS et al, Arquivos Brasileiros de Endocrinologia e Metabologia 2007;51/5:690-700). Uma observação inesperada durante as nossas pesquisas foi a presença da D2 no carcinoma medular da tireóide (CMT). A atividade da D2 em amostras de CMT estava comparável ao tecido folicular normal (0,41 ± 0,10 vs. 0,43 ± 0,41 fmol T4/min/mg proteína, P=0,913). Para descartar a possibilidade de contaminação do tecido tumoral por tecido tireoidiano normal, a investigação foi ampliada para a análise dessa enzima nas células TT, uma linhagem celular humana de CMT. Os resultados confirmaram os achados nas amostras tumorais e evidenciaram a manutenção das propriedades bioquímicas da D2, tais como a inibição pelos hormônios tireoidianos, a insensibilidade à inibição pelo propiltiouracil e a baixa Constante de Michaelis-Menten, apesar da desdiferenciação celular. Sendo assim, os nossos dados propõem uma nova perspectiva sobre o papel dos hormônios tireoidianos nas células C da tireóide (artigo submetido à publicação).

Os carcinomas da tireóide são as neoplasias malignas mais freqüentes do sistema endócrino. Classificam-se histologicamente em carcinomas papilar e folicular, derivados das células foliculares; carcinoma medular, derivado das células C ou parafoliculares, e carcinoma anaplásico. Os carcinomas diferenciados, papilar e folicular, representam mais do que 85% de todos os tipos histológicos. O carcinoma medular, compreende 5 a 10% e o anaplásico ou indiferenciado, 2% de todos os cânceres da tireóide. Os carcinomas diferenciados da tireóide geralmente conservam as características bioquímicas da célula folicular tireoidiana. No entanto, vários estudos têm descrito anormalidades na expressão das principais proteínas envolvidas na biossíntese dos hormônios tireoidianos, tais como o receptor do TSH, o cotransportador de Na+/I- (NIS), a tireoglobulina (Tg) e a tireoperoxidase (TPO). As iodotironinas desiodases tipo 1 (D1) e tipo 2 (D2) são enzimas responsáveis pela ativação do T4 e produção do hormônio biologicamente ativo T3 na tireóide e nos tecidos periféricos. Poucos estudos analisaram a expressão das 5’-desiodases nos carcinomas diferenciados da tireóide. Estudos prévios demonstraram que a expressão da isoenzima D2 está reduzida no carcinoma papilar e aumentada no carcinoma folicular metastático. No entanto, uma expressão variável da D1 foi descrita em amostras de carcinomas papilares, sendo que não havia uma avaliação sistemática da expressão dessa isoenzima nos carcinomas foliculares. O objetivo inicial do nosso estudo foi avaliar a expressão da D1 e da D2 nos tumores benignos e malignos da tireóide. De forma interessante, demonstramos que nos vários subtipos histológicos de carcinoma papilar, inclusive em microcarcinomas, os níveis de RNA mensageiro (RNAm) e de atividade da D1 estavam significativamente diminuídos em relação ao tecido tireoidiano normal correspondente (0,25 ± 0,24 vs. 1,09 ± 0,54 unidades arbitrárias (UA), P<0,001 e 0,08 ± 0,07 vs. 0,24 ± 0,15 pmol T4/min/mg proteína, P=0,045, respectivamente) . Por outro lado, observamos um aumento da expressão dessa enzima nos adenomas (1,9 ± 1,5 vs. 0,83 ± 0,58 UA, P= 0,028 e 2,67 ± 1,42 vs. 0,22 ± 0,06 pmol T4/min/mg proteína, P=0,044, respectivamente) e nos carcinomas foliculares (1,2 ± 0,46 vs. 0,67 ± 0,18 UA, P=0,038 e 1,20 ± 0,58 vs. 0,20 ± 0,10 pmol T4/min/mg proteína, P<0,001, respectivamente). Da mesma forma, confirmamos dados prévios sobre o aumento da atividade da D2 no carcinoma folicular metastático. A análise desses resultados permitiu concluir, originalmente, que a alteração na expressão da D1 parece ser um evento precoce e específico da desdiferenciação celular do carcinoma papilar (Souza Meyer EL et al, Clinical Endocrinology 2005;62:672-78). O interesse pelo padrão de expressão das 5’-desiodases em outros tumores humanos e pelos mecanismos ou implicações do aumento ou da diminuição das desiodases na patogênese neoplásica, determinou um estudo da literatura que foi publicado em artigo de revisão (Meyer ELS et al, Arquivos Brasileiros de Endocrinologia e Metabologia 2007;51/5:690-700). Uma observação inesperada durante as nossas pesquisas foi a presença da D2 no carcinoma medular da tireóide (CMT). A atividade da D2 em amostras de CMT estava comparável ao tecido folicular normal (0,41 ± 0,10 vs. 0,43 ± 0,41 fmol T4/min/mg proteína, P=0,913). Para descartar a possibilidade de contaminação do tecido tumoral por tecido tireoidiano normal, a investigação foi ampliada para a análise dessa enzima nas células TT, uma linhagem celular humana de CMT. Os resultados confirmaram os achados nas amostras tumorais e evidenciaram a manutenção das propriedades bioquímicas da D2, tais como a inibição pelos hormônios tireoidianos, a insensibilidade à inibição pelo propiltiouracil e a baixa Constante de Michaelis-Menten, apesar da desdiferenciação celular. Sendo assim, os nossos dados propõem uma nova perspectiva sobre o papel dos hormônios tireoidianos nas células C da tireóide (artigo submetido à publicação).

Os carcinomas da tireóide são as neoplasias malignas mais freqüentes do sistema endócrino. Classificam-se histologicamente em carcinomas papilar e folicular, derivados das células foliculares; carcinoma medular, derivado das células C ou parafoliculares, e carcinoma anaplásico. Os carcinomas diferenciados, papilar e folicular, representam mais do que 85% de todos os tipos histológicos. O carcinoma medular, compreende 5 a 10% e o anaplásico ou indiferenciado, 2% de todos os cânceres da tireóide. Os carcinomas diferenciados da tireóide geralmente conservam as características bioquímicas da célula folicular tireoidiana. No entanto, vários estudos têm descrito anormalidades na expressão das principais proteínas envolvidas na biossíntese dos hormônios tireoidianos, tais como o receptor do TSH, o cotransportador de Na+/I- (NIS), a tireoglobulina (Tg) e a tireoperoxidase (TPO). As iodotironinas desiodases tipo 1 (D1) e tipo 2 (D2) são enzimas responsáveis pela ativação do T4 e produção do hormônio biologicamente ativo T3 na tireóide e nos tecidos periféricos. Poucos estudos analisaram a expressão das 5’-desiodases nos carcinomas diferenciados da tireóide. Estudos prévios demonstraram que a expressão da isoenzima D2 está reduzida no carcinoma papilar e aumentada no carcinoma folicular metastático. No entanto, uma expressão variável da D1 foi descrita em amostras de carcinomas papilares, sendo que não havia uma avaliação sistemática da expressão dessa isoenzima nos carcinomas foliculares. O objetivo inicial do nosso estudo foi avaliar a expressão da D1 e da D2 nos tumores benignos e malignos da tireóide. De forma interessante, demonstramos que nos vários subtipos histológicos de carcinoma papilar, inclusive em microcarcinomas, os níveis de RNA mensageiro (RNAm) e de atividade da D1 estavam significativamente diminuídos em relação ao tecido tireoidiano normal correspondente (0,25 ± 0,24 vs. 1,09 ± 0,54 unidades arbitrárias (UA), P<0,001 e 0,08 ± 0,07 vs. 0,24 ± 0,15 pmol T4/min/mg proteína, P=0,045, respectivamente) . Por outro lado, observamos um aumento da expressão dessa enzima nos adenomas (1,9 ± 1,5 vs. 0,83 ± 0,58 UA, P= 0,028 e 2,67 ± 1,42 vs. 0,22 ± 0,06 pmol T4/min/mg proteína, P=0,044, respectivamente) e nos carcinomas foliculares (1,2 ± 0,46 vs. 0,67 ± 0,18 UA, P=0,038 e 1,20 ± 0,58 vs. 0,20 ± 0,10 pmol T4/min/mg proteína, P<0,001, respectivamente). Da mesma forma, confirmamos dados prévios sobre o aumento da atividade da D2 no carcinoma folicular metastático. A análise desses resultados permitiu concluir, originalmente, que a alteração na expressão da D1 parece ser um evento precoce e específico da desdiferenciação celular do carcinoma papilar (Souza Meyer EL et al, Clinical Endocrinology 2005;62:672-78). O interesse pelo padrão de expressão das 5’-desiodases em outros tumores humanos e pelos mecanismos ou implicações do aumento ou da diminuição das desiodases na patogênese neoplásica, determinou um estudo da literatura que foi publicado em artigo de revisão (Meyer ELS et al, Arquivos Brasileiros de Endocrinologia e Metabologia 2007;51/5:690-700). Uma observação inesperada durante as nossas pesquisas foi a presença da D2 no carcinoma medular da tireóide (CMT). A atividade da D2 em amostras de CMT estava comparável ao tecido folicular normal (0,41 ± 0,10 vs. 0,43 ± 0,41 fmol T4/min/mg proteína, P=0,913). Para descartar a possibilidade de contaminação do tecido tumoral por tecido tireoidiano normal, a investigação foi ampliada para a análise dessa enzima nas células TT, uma linhagem celular humana de CMT. Os resultados confirmaram os achados nas amostras tumorais e evidenciaram a manutenção das propriedades bioquímicas da D2, tais como a inibição pelos hormônios tireoidianos, a insensibilidade à inibição pelo propiltiouracil e a baixa Constante de Michaelis-Menten, apesar da desdiferenciação celular. Sendo assim, os nossos dados propõem uma nova perspectiva sobre o papel dos hormônios tireoidianos nas células C da tireóide (artigo submetido à publicação).

Submitted by Valquíria Barbieri (kikibarbi@hotmail.com) on 2018-04-18T21:12:08Z No. of bitstreams: 1 DISS_2015_Deise Fátima Mezaroba.pdf: 1567664 bytes, checksum: 67bbe66382033d0b60709a1c450df069 (MD5) / Approved for entry into archive by Jordan (jordanbiblio@gmail.com) on 2018-04-27T17:30:42Z (GMT) No. of bitstreams: 1 DISS_2015_Deise Fátima Mezaroba.pdf: 1567664 bytes, checksum: 67bbe66382033d0b60709a1c450df069 (MD5) / Made available in DSpace on 2018-04-27T17:30:42Z (GMT). No. of bitstreams: 1 DISS_2015_Deise Fátima Mezaroba.pdf: 1567664 bytes, checksum: 67bbe66382033d0b60709a1c450df069 (MD5) Previous issue date: 2015-04-30 / CAPES / A dieta hipoproteica-hiperglicídica (LPHC), administrada a ratos machos por 15 ou 45 dias, logo após o desmame, altera vários parâmetros metabólicos e hormonais. Sabe-se também que os hormônios produzidos pela glândula tireoide têm um papel fundamental a nível tecidual para a manutenção da homeostase do organismo. Diante disto, o objetivo deste trabalho foi investigar os efeitos da dieta LPHC a longo prazo e da troca da dieta LHPC por dieta balanceada sobre o metabolismo desiodativo em diferentes tecidos, assim como algumas das ações atribuídas aos hormônios tireóideos. Ratos Wistar machos (~100g) foram randomicamente divididos em grupos conforme segue: 1) controles - alimentados com uma dieta com 17% de proteínas e 63% de carboidratos por 45 dias (C45); 2) LPHC - alimentados com dieta contendo 6% de proteínas e 74% de carboidratos por 45 dias (LPHC45) e; 3) reversão - alimentados por 15 dias com a dieta LPHC e por mais 30 dias com a dieta controle (R) (ANOVA-1 via; p<0,05). A quantificação da concentração do hormônio tireoestimulante no sangue dos animais do grupo R mostrou um aumento de 11,7% e 11,6%, se comparado ao grupo C45 e ao grupo LPHC45, respectivamente (C45: 8439,58 ± 59,46; LPHC45: 8448,06 ± 105,86; R: 9428,39 ± 48,96 pg/mL). A análise da expressão proteica da iodotironina desiodase 1 em fígado, rins e tireoide e da iodotironina desiodase 2 em tecido adiposo marrom, músculos extensor digital longo e sóleo, hipotálamo e hipófise mostrou alteração somente no fígado do grupo LPHC45, com aumento de 17,38% da isoforma 1, em relação aos animais controles. Este grupo também apresentou aumento de 27,02% no conteúdo do receptor hepático para hormônio tireóideo β1, comparando-se ao grupo C45. A avaliação do perfil lipídico de jejum mostrou redução do colesterol total (C45: 97,35 ± 7,87; LPHC45: 65,41 ± 4,78; R: 94,32 ± 5,25 mg/dL), colesterol HDL (C45: 56,58 ± 3,90; LPHC45: 36,74 ± 1,28; R: 54,21 ± xvii 4,30 mg/dL), colesterol VLDL (C45: 22,92 ± 1,44; LPHC45: 15,89 ± 1,50; R: 22,07 ± 1,70 mg/dL) e triglicerídeos (C45: 114,61 ± 7,18; LPHC45: 79,46 ± 7,49; R: 110,36 ± 8,48 mg/dL) nos animais submetidos à dieta LPHC por 45 dias. A expressão hepática da enzima 7α-hidroxilase e da proteína de ligação ao elemento de resposta aos esteróis aumentou 43,96% e 36,27%, respectivamente, no grupo LPHC45, quando comparadas ao grupo C45. A atividade das enzimas málica (C45: 85,92 ± 9,01; LPHC45: 171,63 ± 14,98; R: 159,09 ± 13,16 nmol.mg prot-1.min-1) e ATP-citrato liase (C45: 290,88 ± 11,57; LPHC45: 444,98 ± 20,79; R: 386,75 ± 23,47 nmol.mg prot-1.min-1) foi maior nos grupos LPHC45 e R, em relação ao grupo C45. A análise conjunta destes dados demonstra que a dieta hipoproteica-hiperglicídica administrada por 45 dias leva a alterações no metabolismo desiodativo hepático, modulando o perfil lipídico e que talvez possam resultar em um futuro quadro de esteatose hepática. / The low-protein, high-carbohydrate diet (LPHC) administered to male rats for 15 or 45 days after weaning, change various metabolic and hormonal parameters. It is also known that the hormones produced by the thyroid gland have a key role to tissue level to maintain body’s homeostasis. Thus, the objective of this study was to investigate the effects of the LPHC diet long-term and exchange of LHPC diet for balanced diet on the deiodinative metabolism in different tissues, as well as some of the actions attributed to thyroid hormone. Male Wistar rats (~100g) were randomly divided into the following groups: 1) controls - fed a diet containing 17% protein and 63% carbohydrates for 45 days (C45 group); 2) LPHC - fed a diet containing 6% protein and 74% carbohydrates for 45 days (LPHC45 group), and 3) reversal - fed for 15 days with LPHC diet and for 30 days with the control diet (R group) (ANOVA-one way; p<0.05). The quantification of the concentration of thyroid-stimulating hormone in the blood of the animals of the R group showed an increase of 11.7% and 11.6%, compared with the C45 group and LPHC45 group, respectively (C45: 8439.58 ± 59.46; LPHC45: 8448.06 ± 105.86; R: 9428.39 ± 48.96 pg/mL). Analysis of protein expression of iodothyronine deiodinase 1 in liver, kidney and thyroid, and protein expression of iodothyronine deiodinase 2 in brown adipose tissue, long digital extensor and soleus muscles, hypothalamus, and pituitary only showed alteration in liver of the LPHC45 group, with an increase of 17.38% in the isoform 1, compared with the control animals. This group also showed an increase of 27.02% in the content of liver receptor for thyroid hormone β1 compared with the C45 group. The fasting lipid profile showed a reduction in total cholesterol (C45: 97.35 ± 7.87; LPHC45: 65.41 ± 4.78; R: 94.32 ± 5.25 mg/dL), in HDL cholesterol (C45: 56.58 ± 3.90; LPHC45: 36.74 ± 1.28, R: 54.21 ± 4.30 mg/dL), in VLDL (C45: 22 92 ± 1.44; LPHC45: 15.89 ± 1.50; R: 22.07 ± 1.70 mg/dL), xix and triglycerides (C45: 114.61 ± 7.18; LPHC45: 79.46 ± 7 49; R: 110.36 ± 8.48 mg/dL) in animals subjected to LPHC diet for 45 days. The hepatic expression of 7α-hydroxylase enzyme and the binding protein sterol response element had an increase of 43.96% and 36.27%, respectively, in LPHC45 group when compared with the C45 group. The activity of malic enzyme (C45: 85.92 ± 9.01; LPHC45: 171.63 ± 14.98; R: 159.09 ± 13.16 nmol.mg prot-1 .min-1) and ATP-citrate lyase (C45: 290.88 ± 11.57; LPHC45: 444.98 ± 20.79; R: 386.75 ± 23.47 nmol.mg prot-1 .min-1) was higher in LPHC45 and R groups, compared with C45 group. The analysis of these data shows that the low-protein, high-carbohydrate diet administered for 45 days leads to alterations in hepatic deiodinative metabolism by modulating the lipid profile and that may perhaps result in a future framework of hepatic steatosis.

Thyroid hormones (THs; T4 and T3), secreted from thyroid gland, play an important role in human growth and development. T3 (3,5,3′-triiodothyronine) is the active hormone and the conversion of T4 (3,3′,5,5′-tetraiodothyronine) to T3 in cells is mediated by iodothyronine deiodinases enzymes (DIOs). DIOs are selenocysteine containing enzymes and are classified into three types (DIO1, DIO2 and DIO3). DIO1 catalyzes the outer-ring deiodination (ORD; T3 formation) and inner-ring deiodination (IRD; rT3 formation) reactions, involving in the activation (T4 to T3 conversion) and inactivation (T4 to rT3 conversion), respectively. DIO2 and DIO3 catalyse the ORD and IRD reactions, respectively. This homeostasis is regulated tightly and any deviation would lead to diseases like hyperthyroidism or hypothyroidism. Recently it is of interest to many research groups to develop iodothyronine deiodinase mimics and we have developed naphthalene-based peri-substituted thioselenol pair at 1,8-positions (1.25), which remove iodine selectively from inner-ring of T4. When selenium atom is substituted in place of sulfur (selenol-selenol pair; 1.26), the deiodination activity was ca. 90 times faster than with 1.25. This thesis deals with various aspects of the effect of substituents on the naphthalene-1,8-diselenol and solvent effect on the thyroid hormone deiodination by naphthalene-based iodothyronine deiodinase mimics. Figure 1. (A) Deiodination reactions by DIOs. (B) Chemical structure of 1.25 and 1.26. The thesis consists of five chapters. The first chapter provides a general overview about sialoproteins, thyroid hormone biosynthesis, thyroid hormone metabolism, halogen bonding, iodothyronine deiodinase mimics and proposed mechanisms for the deidoination of thyroid hormones. This chapter also introduces peri-naphthalene-1,8-diselenol (1.26), which is the key compound in this thesis and discusses about proposed mechanism for the deiodination of thyroxine involving co-operative halogen bonding and chalcogen bonding mechanism. Figure 2. (A) TH action. (B) Proposed mechanism for the deiodination of T4 by 1.26 involving cooperative halogen bonding and chalcogen bonding. Chapter 2 discusses about the synthesis, characterization and deiodination activity of a series of naphthalene-based peri-substituted-1,8-diselenols (Figure 3). These diselenols regioselectivity remove iodine from inner ring of thyroxine and other thyroid hormones, (T3 and 3, 5-T2). Substitution with different groups on the naphthalene ring did not change the regioselectivity of deiodination, indicating that the deiodination activity does not depend on the nature of substituents. Secondary or tertiary amine side chain group attached at the 2nd position of the naphthalene ring showed better activity. It is due to the secondary interaction, which facilitates the iodine removal. It was further confirmed with the substitutions at the 4th position of the ring to discriminate the possibility of electronic effect. The higher deiodination rate owing to the t-butyl group at second position of the ring also suggests that the steric effect may also play a role in the deiodination reaction (Figure 4). It is proposed that peri substituted naphthalene-1,8-diselenols remove iodine from thyroid hormones through halogen bonding-chalcogen bonding mechanism (Figure 2). The investigation of Se···Se bond distance from the crystal structures and through DFT calculation and NMR experiment showed that the stronger chalcogen bond could be the reason for the increase in the reactivity observed with substituted peri-naphthalene-1,8-diselenols. Figure 3. peri-substituted naphthalene-1,8-diselenols used for the study. Figure 4. Relative deiodinase activity of substituted-peri-naphthalene-1,8-diselenols with T4. In Chapter 3, we have discussed about the effect of chalcogen atom substitution in a series of deiodinase mimics on the deiodination of thyroid hormones. Moving from thiol-selenol pair (1.25) to selenol-selenol pair (1.26) in naphthalene based peri-substituted mimics, an increase in the activity was observed. In this chapter, we have shown that substituting with tellurium, as tellurium-thiol pair (3.3) and ditellurol (3.4) increases the reactivity of deiodination to several times and also regioselectivity of deiodination is changed from IRD in the case of 1.26 to both IRD and ORD for 3.3 and 3.4. The presence of two tellurol moieties (3.4) or a thiol-tellurol pair (3.3) can mediate sequential deiodination of T4, to produce all the possible thyroid hormone derivatives under physiologically relevant conditions (Figure 5). This study provided the first experimental evidence that the regioselectivity of the thyroid hormone deiodination is controlled by the nucleophilicity and the strength of halogen bond between the iodine and chalcogen atoms. Figure 5. (A) HPLC chromatograms of deiodination reaction of T4 with 3.3 and 3.4. (B) Chemical structure of 3.3 and 3.4. (C) Sequential deiodination reaction of T4 by 3.3 and 3.4. Chapter 4 describes the effect of alkyl conjugation at 4′-OH position of THs on the deiodination by iodothyronine mimics. In addition to the deiodination, iodothyronines undergo conjugation with sulfate and glucuronic acid group at 4′-hydroxyl position. Conjugation alters the physico-chemical properties of iodothyronines. For example, it is known that sulfate conjugation increases the rate of deiodination to a large extend. We have conjugated alkyl group at 4′-hydroxyl position of iodothyronines and investigated the deiodination reactions with reported peri-substituted naphthalene-1,8-diselenols. We observed that similar to sulfated thyroid hormones O-methylthyroxine also undergoes both phenolic and tyrosyl ring deiodination reactions and overall the rate of deiodination is increased at least by 5 times as compared with T4 under identical conditions. The phenolic iodine removal is favored by conjugation as compared to the tyrosyl ring iodine, which is similar to the observation made for T4S. Interestingly, when the acetamide group is conjugated at 4′-OH position, the regioselectivity of deiodination is changed exclusively to 5′-iodine. DFT calculations show that the positive potential on the iodine increase upon conjugation, which leads to stronger halogen bonding interaction with selenol, might be the reason for the change in the regioselectivity of deiodination. Figure 6. (A) HPLC chromatogram of deiodination reaction of T4(Me) with 1.26. (B) Initial rate comparison of T4 and T4(Me).(C) HPLC chromatogram of deiodination reaction of T4(AA) with 1.26 showing the formation of T3(AA) (ORD product). (D) Electron potential map of T4, T4(Me) and T4(AA) showing the increase in electro positive potential on 5′-iodine upon conjugation. Chapter 5 deals with the solvent effect on the deiodination reactions of THs by iodothyronine deiodinase mimics. As discussed in the earlier chapters, the deiodination reaction of thyroxine by naphthalene based-1,8-diselenols under physiological conditions produce, rT3 (IRD) as the only observable products. Surprisingly, when the deiodination reaction was performed in DMF or DMSO in the presence of 1.26, the regioselectivity of reaction was changed and the formation of both T3 (ORD) and rT3 was observed. In DMF or in DMSO, the deiodination reactivity of 1.26 was found to be 1000 fold higher than the reaction performed in phosphate buffer at pH 7.4. Figure 7. (A) HPLC chromatogram for the deiodination reaction of T4 in DMF by 1.26 showing both IRD and ORD. (B) A comparison of initial rate for the deiodination reactions of T4, T3 and 3,5-T2 in DMF and in DMSO by 1.26. (C) HPLC chromatograms for the deiodination reaction of T4 in DMF by 1.26 in the presence of TEMPO, showing the inhibition of deiodination (i) 0 mM TEMPO (ii) 10 mM of TEMPO (iii) 30 mM TEMPO. (D) HPLC chromatograms for the deiodination reaction of T4 in DMSO by 1.26 in the presence of TEMPO showing the inhibition of deiodination (i) 0 mM TEMPO (ii) 10 mM of TEMPO (iii) 30 mM TEMPO. 3,5-DIT was not denominated under physiological conditions, however, in DMF and in DMSO, 3,5-DIT was deiodinated by 2.4 to produce 3-MIT. We also observed that the control reactions in DMF or DMSO also showed a little deiodination activity. The very high reactivity observed in the presence of DMF or DMSO implied that the mechanism of denomination in these solvents may be different. It has been reported that DMSO or DMF radicals can be formed with small amounts of a base. Reaction mixture consisting of NaBH4 (for generating selenol from diselenide) and NaOH (T4 solution) may facilitate the radical formation. We also performed the reaction in the presence of TEMPO (free radical scavenger) and observed the inhibition of deiodination reaction. However, it is not clear whether the radical pathway could be one of the possible mechanisms of deiodination in these solvents by compounds 1.26 and 2.4. Further studies are required to propose a radical mechanism in different solvents such as DMF and DMSO.

Thyroid hormones, which are secreted by the thyroid gland, are one of the most important halogenated compounds in the body. Thyroid hormones control almost every processes in the body including growth, body temperature, protein synthesis, carbohydrate and fat metabolism, heart rate, and cardiovascular, renal and brain function. Thyroid gland secretes L-thyroxine or 3,3',5,5'-tetraiodothyronine (T4) as a prohormone. While the biologically active hormone 3,3',5-triiodothyronine (T3) is produced by selective phenolic ring deiodination of T4, selective tyrosyl ring deiodination of T4 produces a biologically less active metabolite 3,3',5'-triiodothyronine (rT3). Tyrosyl and phenolic ring deiodination of T3 and rT3, respectively, also produces a biologically inactive metabolite 3,3'-diiodothyronine (3,3'-T2). Regioselective deiodinations of thyroid hormones are catalysed by three isoforms of a selenoenzyme iodothyronine deiodinase (DIO1, DIO2, DIO3). DIO1 can remove iodine from both the tyrosyl and phenolic rings of thyroid hormones, whereas DIO2 and DIO3 are selective towards phenolic and tyrosyl ring, respectively. Although the Figure 1. (A) Deiodination of thyroid hormones by iodothyronine deiodinases (DIOs) (A) and naphthyl-based selenium and/or sulphur compounds (B). mystery behind the origin of regioselectivity of deiodination by DIOs remains unsolved, formation of halogen bonding between selenium in the active site of DIOs and iodine of thyroid hormones has been widely accepted as the mechanism of deiodination. Halogen bonding, a noncovalent interaction between halogen and an electron donor such as nitrogen, oxygen, sulphur, selenium etc., elongates the C-I bond and impart a carbanionic character on the carbon atom that gets protonated after the removal of iodide. Apart from the deiodination, thyroid hormones also undergo decarboxylation, oxidative deamination, sulphate-conjugation to form iodothyronamines, iodothyroaetic acids and sulphated thyroid hormones, respectively. Figure 2. (A) Proposed mechanism of deiodination of thyroid hormones by deiodinase mimics. (B) Halogenation of uracil- and cytosine-containing nucleosides by hypohalous acid (HOX). Recently, naphthyl-based selenium/sulphur-containing compounds, such as compound 1 (Figure 1B), have been reported to mediate the selective tyrosyl ring deiodination of T4 and T3 to form rT3 and 3,3'-T2, respectively. Interestingly, replacement of the selenol moiety in compound 1 with a thiol decreases the activity, whereas replacement of the thiol moiety with another selenol dramatically increases the deiodination activity. Based on the detailed experimental and theoretical investigations, a mechanism involving the Se···I halogen bonding was proposed (Figure 2A). In addition to the halogen bonding between selenium and iodine atom, chalcogen bonding between two nearby chalcogen atoms was also shown to be important for the deiodination activity. Another important class of halogenated compounds in the body are the halogenated nucleosides. Myeloperoxidase and eosinophil peroxidase are heme-containing enzymes, which can convert halide ions (X¯) into a toxic reactive halogen species hypohalous acid (HOX) in presence of hydrogen peroxide (H2O2). Uracil- and cytosine-containing nucleosides are known to undergo halogenation at the 5-position of the nucleobase to form the halogenated nucleosides (Figure 2B). Interestingly, halogenated nucleosides such as 5-halo-2'-deoxyuridine are known to be incorporated in the DNA of dividing cells essentially substituting for thymidine. Incorporation of halogenated nucleosides into the DNA leads to mutagenesis, carcinogenesis and loss of genome integrity. Thymidylate synthase (TSase), the key enzyme involved in the biosynthesis of 2'-deoxythmidine-5'-monophosphate (dTMP) from 2'-deoxyuridine-5'-monophosphate (dUMP), can catalyse the dehalogenation of halogenated nucleotides in presence of external thiols. This thesis consists of five chapters. The first chapter provides a general introduction to halogen bonding, thyroid hormones and halogenated nucleosides. This chapter also briefly describes the halogen bond-mediated biochemical and biomimetic deiodinations of thyroid hormones by iodothyronine deiodinases and naphthyl-based organoselenium compounds. Dehalogenation of halogenated nucleotides by thymidylate synthase and thiol-based small molecules has also been discussed in this chapter. The second chapter of this thesis contains the regioselective deiodination of iodothyronamines (TAMs) by deiodinases mimics. TAMs are the endogenous metabolites produced by the decarboxylation of β-alanine side chain of thyroid hormones (THs). 3,3',5-triiodothyronamine (T3AM) and 3,5-diiodothyronamine (3,5-T2AM) undergoes selective tyrosyl ring deiodination by deiodinase mimics to form 3,3'-diiodothyronamine (3,3'-T2AM) and 3-iodothyronamine (3-T1AM), respectively. Interestingly, when the initial rates of deiodinations of T3 and T3AM were compared, deiodination of T3 was found to be several fold faster than that of T3AM under identical reaction conditions. To understand the ability of the iodine atoms to form Figure 3. (A) HPLC chromatogram of deiodination of T3. (B) Proposed mode of interaction of dimeric T3 and monomeric T3AM with organoselenium compounds. halogen bonding, a model selenolate (MeSe¯) was optimized with the T3 and T3AM. Although both T3 and T3AM forms the expected Se···I halogen bonding with MeSe¯, the strength of halogen bonding was found to be less for T3AM than T3. Furthermore, detailed kinetic and spectroscopic studies indicate that T3 and T3AM exist as dimeric and monomeric species in solution. The dimerization of T3 in solution was shown to have remarkable impact on the activation energy and pre-exponential factor of the deiodination reactions. Single crystal X-Ray crystallography and theoretical calculations indicated that in addition to Se···I halogen bonding, I···I halogen bonding may play an important role in the deodination of thyroid hormones by deiodinase mimics. Furthermore, the presence of heteroatoms such as nitrogen, oxygen and sulphur in the close proximity of one of the selenium atoms of deiodinase mimics was shown to have significant effect on the rate of deiodination reactions. The third chapter of the thesis focusses on the conformational polymorphism and conformation-dependent halogen bonding of L-thyroxine. Synthetic version of L-thyroxine (T4) is a life-saver for millions of people who are suffering from hypothyroidism, a thyroidal disorder recognised by low levels of T4 and elevated levels of TSH in blood plasma. Synthetic version of L-thyroxine is available in the Figure 4. Ball and stick model of the single crystal X-Ray structure of the conformational polymorphs of L-thyroxine. Form I and Form II was exclusively crystallized from methanol and acetonitrile, respectively. Water molecules are omitted for clarity. market with various brand names. However, adverse effects have been observed in the patients when they switch their brand of thyroxine. Based on these observations, the American Thyroid Association (ATA), the Endocrine Society (TES), and the American Association of Clinical Endocrinologists (AACE) declared that the different brands of T4 are not bioequivalent, thus leading to differences in the bioavailability of the drug. We have shown that the commercially available thyroxine exists in at least two stable forms (Form I and Form II) with different three-dimensional structures (Figure 4). These two forms exhibit different intermolecular interactions in crystal packing, spectral behaviours, thermal stabilities, optical activity and very interestingly, different solubility in acidic and basic pH. At pH 4, solubility of Form I is about 42% and 45% greater than that of Form II and bulk T4, respectively, whereas at pH 9, the solubility of Form II is about 38% and 42% higher than that of Form I and bulk T4, respectively. As T4 is a narrow therapeutic index drug, these differences in solubility may have remarkable impact on the bioavailability of the drug. In addition to this, we have shown that the ability of the iodine atoms in the C-I bonds to form halogen bond with donor atoms can be altered by changing the relative orientation of tyrosyl and phenolic rings in T4. In the fourth chapter, the three-dimensional structures and conformations of thyroid hormones (THs) and iodothyronamines (TAMs) are discussed. TAMs, the endogenous decarboxylated metabolites of THs, exhibit different binding affinities to the transport proteins and iodothyronine deiodinases (DIOs) compared to the THs. Figure 5. Change in the structure and conformations of thyroid hormones and iodothyronamines with the decarboxylation of amino acid side chain and deiodination of phenolic and tyrosyl ring. Furthermore, the substrate specificities of DIOs have been found to be dependent on the position of iodine atoms on the phenolic and tyrosyl ring of TAMs and THs. Single crystal X-ray structures of TAMs indicate that decarboxylation of amino acid side chain of THs induces significant changes in the structure and conformation. Furthermore, the positional isomers of THs and TAMs exhibit remarkably different conformations, which may have significant effect on the binding of these metabolites to the active site of DIOs. In addition to the structure and conformations, different categories of the intermolecular halogen···halogen (X···X) interactions in the crystal packing of THs and TAMs have also been discussed. Natural bond orbital (NBO) analysis have been done on the halogen-bonded geometries to understand the electronic nature of these interactions. In the fifth chapter, the dehalogenation of halogenated nucleosides and nucleobases by naphthyl-based sulphur/selenium compounds is discussed. Purine and pyrimidine nucleosides are halogenated at various positions of the aromatic ring by different peroxidases such as myeloperoxidase and eosinophil peroxidase present in the white blood cells. Incorporation of the halogenated nucleosides into the DNA of replicating cells leads to DNA-strand breaks, mutagenesis, carcinogenesis and loss of Figure 6. (A) Dehalogenation of halogenated nucleosides. Effect of base-pairing wih adenine and guanine on the deiodination of IU (B) and debromination of BrU (C) by compound 2. genome integrity. We have shown that the naphthalene-based organoselenium compounds such as compound 2 can mediate the dehalogenation of 5-iodo-2'-deoxyuridine (5-IdUd) and 5-bromo-2'-deoxyuridine (5-BrdUd) to produce 2'-deoxyuridine (dUd) (Figure 6A). The deiodination of 5-IdUd was found to be faster than the debromination of 5-BrdUd by compound 2. The mechanism of dehalogenation of halogenated nucleosides by compound 2 was found to be dependent on the nature of halogen. While the deiodination of 5-IdUd by compound 2 follow halogen bond-mediated pathway like thyroid hormones, debromination of 5-BrdUd follow a Michael addition-elimination pathway. Similar results were obtained when 5-iodo-2'-deoxycytidine (5-IdCd) or 5-bromo-2'-deoxycytidine (5-BrdCd) was used as substrate for dehalogenation reaction. Base-pairing of 5-iodouracil (IU) and 5-bromouracil (5-BrU) with adenine and guanine has a significant effect on the rate of dehalogenations of IU and BrU by compound 2 (Figure 6B and 6C).

Thyroxine is the main secretory hormone of thyroid gland and it is produced in thyroglobulin by thyroid peroxidase/hydrogen peroxide/iodide system. After biosynthesis and secretion of thyroxine, it undergoes multiple metabolic reactions. The most important metabolic pathway is the stepwise deiodination from the inner ring or outer ring. Removal of one of the outer ring or phenolic ring iodines of biologically less active T4, leads to the formation of 3,5,3'-triiodothyronine or T3, a compound which is biologically more active. On the other hand, removal of one of the inner ring or tyrosyl ring iodines gives 3,3',5'-triiodothyronine (3,3',5'-T3 or rT3) which is a biologically inactive thyroid hormone. Three enzymes involved in this activation and inactivation pathway of thyroid hormones are known as iodothyronine deiodinases (IDs), which are dimeric integral-membrane selenoproteins. Depending upon the sequence and substrate specificity, three iodothyronine deiodinase enzymes have been identified, iodothyronine deiodinase-1 (ID-1), iodothyronine deiodinase-2 (ID-2) and iodothyronine deiodinase-3 (ID-3). ID-1 can catalyze both inner ring and outer ring deiodination of thyroid hormones whereas, ID-2 is selective to the outer ring deiodination. The type-1 and -2 deiodinases (ID-1 and ID-2) produces the biologically active hormone 3,5,3′-triiodothyronine (T3). These two enzymes also convert 3,3′,5′-triiodothyronine (reverse T3 or rT3) to 3,3′-diiodothyronine (3,3′-T2) by outer-ring deiodination (Scheme 1). The type-3 deiodinase (ID-3) catalyzes the convertion of T4 to rT3 by an inner-ring deiodination pathway. Apart from deiodination, there are several alternate pathways of thyroid hormone metabolism, which include sulfate conjugation and glucoronidation of the phenolic hydroxyl group of iodothyronines, the oxidative deamination and decarboxylation of the alanine side chain to form thyroacetic acid and thyronamines, respectively. Glucoronidation and sulfate conjugation changes the physico-chemical properties of iodothyronines dramatically. This thesis consists of five chapters. The first chapter provides a general introduction of biosynthesis of thyroid hormones and followed by deiodination by three iodothyronine deiodinase enzyme. This chapter also provides an overview of thyroid hormone transport and different transport proteins and their mode of binding with thyroid hormones. Apart from this, this chapter also provides a brief overview on other thyroid hormone metabolites. In the second chapter of the thesis, initial attempts in the development of different iodothyronine deiodinase mimics have been discussed. Goto et al have shown that the sterically hindered selenol 1 converts the thyroxine derivative 3 (N¬butyrylthyroxine methyl ester) to the corresponding triiodo derivative 4 by an outer-ring deiodination (Scheme 2). Although the reaction was carried out in organic solvent and a relatively higher temperature (50 °C) and longer reaction time (7 days) were required for about 65% deiodination, this study also provides an experimental evidence for the formation of selenenyl iodide (2) in the deiodination of a thyroxine derivative by an organoselenol. However, only one iodine was removed from the outer ring of 3, no inner ring deiodination was detected (Scheme 2). Interestingly, when compound 5 was treated with selenol 1 under similar conditions, no deiodination was observed (Scheme 3). This leads to assumption that presence of free phenolic hydroxyl group is important for the deiodinase activity. Based on this experimental observation, they proposed a mechanism which involves an enol¬keto tautomerism of the phenolic hydroxyl group. In the case of thyroxine, the outer-ring can undergo enol-keto tautomerism, whereas due to lack of free hydroxyl group, the inner ring cannot undergo similar kind of tautomerism. The enol-keto tautomerism probably makes the outer ring iodines more reactive than the inner ring iodines of thyroxine. We have developed tthe first chemmical modell for the inneer ring deioddination of TT4 and T3 by type 33 deiodinase . We have shown that naphthyl-baseed selenol 6 bearing a thhiol group in the cloose proximitty to the sellenium act aas an excelleent model foor ID-3 by selectively deiodinatting T4 andd T3 to prodduce rT3 annd 3,3'-T2, rrespectively,, under physiological relevant conditions. When 2 equuivalent of ccompound 66 was emplooyed in the assay, an almost quuantitative cconversion oof T4 to rT3 was observeed within 300 hours and there was no indicaation of the fformation off T3 or 3,3'-TT2. When the selenol group was repplaced with a thiol group in compouund 7, the ddeiodinase activity wwas decreassed. On thee other handd, when thee thiol groupp was replaaced with selenol mmoiety in commpound 8, thhe deiodinasse activity drramatically iincreased wiithout any change iin the selecttivity. Comppounds 10 and 11 havving N-methhylamino grooup were found too be more aactive than the correspponding unssubstituted ccompounds 7 and 8, respectively. However, introduction of a secondary amine adjacent to the selenol moiety into the compound 9 significantly reduces the deiodinase activity. In the third chapter synthesis, deiodinase activity and mechanism of deiodination of a series of peri-substituted naphthalene derivatives is discussed. Iodobenzene was used as halogen bond donor for the DFT calculations. From the orbital analysis it is observed that there is perfect orbital symmetry match between the HOMO of compound 8 (selenolate form) and LUMO of iodobenzene. When the selenolate form of 1-selenonaphthol interacts with iodobenzene, a halogen bonded adduct is formed. The negative charge on the selenium center decreases as it donates electron pair to the σ* orbital of C–I bond in iodobenzene and as a consequence the positive charge on the iodine center decreases (Figure 1). Addition of iodobenzene to 1-selenonaphthol led to a significant downfield shift in 77Se NMR spectrum of 1-selenonaphthol and with an increase in the concentration of iodobenzene, more downfield shift in the signal was observed. Figure 1. The charges obtained from Natural Bond Orbital (NBO) analysis for the selenolate form of (a) 1-selenonaphthol (b) iodobenzene, (c) halogen-bonded adduct On the basis of experimental end theoretical data, a mechanism for the deiodination of T4 by compound 8 is proposed. According to the mechanism, the initial interaction of one of the selenol moieties with an iodine leads to the formation of halogen bond. The transfer of electron density from selenium to the σ* orbital of the C−I bond generates a σ-hole or partial positive charge on the selenium atom, which facilitates an interaction between the halogen bonded selenium atom and the free selenol (selenolate) moiety (intermediate 12). The selenium−selenium interaction (chalcogen bond) strengthens the halogen bond, leading to a heterolytic cleavage of the C−I bond. The protonation of the resulting carbanion leads to the formation of rT3. On the other hand, the formation of an Se−Se bond produces the diselenide 13 with elimination of iodide as HI. The reductive cleavage of the Se−Se bond in compound 13 regenerates the diselenol 8 (Figure 2). In the fourth chapter deiodination of sulfated thyroid hormones is discussed. Sulfate conjugation is an important step in in the irreversible inactivation of thyroid hormones. Sulfate conjugation of the phenolic hydroxyl group stimulates the inner ring deiodination of T4 and T3 but it blocks the outer ring deiodination of T4 by ID-1. The thyroxine sulfate (T4S) undergoes faster deiodination as compared to the parent thyroid hormone T4. Only ID-1 catalyzes the deiodination of sulfated thyroid hormones. In contrast, ID-2 and ID-3 do not accept T4S and/or T3S as substrate. We have shown that iodothyronine sulfates can be readily deiodinated by synthetic deiodinase model compound 8 and its derivatives. In contrast to the inner ring-selective deiodination of T4, the synthetic compounds loses the selectivity and mediate both inner and outer-ring deiodination of T4S and outer ring deiodination of rT3S. From this study, we have also proposed that the enol-keto tautomerism is probably not required for the outer ring deiodination and the strength of halogen bonding controls the regioselective deiodination by model compounds. In the fifth chapter, the mechanism of inhibition of iodothyronine deiodinases by PTU and IAA is discussed with the help of model compounds. In the model study, it has been observed that compound 8 does not form a stable Se-I intermediate (14), which is essential for the formation of Se-S covalent bond with PTU. As a consequence, the deiodination of T4 by compound 8 is not inhibited by PTU. This study supports the proposal that ID-3 does not follow a ping-pong bi-substrate pathway for deiodination and may not form a stable E-Se-I intermediate, which is responsible for the insensitivity of ID-3 towards PTU. The biphenyl based diselenol 15 reacts with IAA and iodoacetamide to form the corresponding carboxymethylated product 17. On the other hand, compound 8 does not undergo the expected carboxymethylation by IAA and iodoacetamide, but they readily deiodinate both IAA and iodoacetamide. Based on this model study, a possible model is proposed for the insensitivity of ID-3 towards IAA. Iopanoic acid (18) is a well known radiocontrast agent and is used as adjunctive therapy with PTU and CBZ for the treatment of thyrotoxicosis.[9] We show in this chapter that iopanoic acid undergoes monodeiodination by compound 8 under physiological relevant conditions. The deiodinated products (19 and 20) from iopanoic acid are characterized by NMR spectroscopy and single crystal X-ray crystallography. It is observed that after monodeiodination, the strength of halogen bonding decreases and therefore, the monodeiodinated products do not undergo further deiodination.